New hope for High-Risk women: can acolbifene outdo tamoxifen in breast cancer prevention?

NCT ID NCT05941520

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 32 times

Summary

This study tests two drugs, acolbifene and low-dose tamoxifen, to see which works better at preventing breast cancer in premenopausal women at high risk. Both drugs block estrogen from fueling breast cell growth. About 80 women will take one of the drugs for six months, and researchers will measure changes in breast tissue, blood, and imaging to assess cancer risk reduction.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Kansas Cancer Center

    RECRUITING

    Kansas City, Kansas, 66160, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.